OptiNose (OPTN) 10-Q 11 Aug 22 2022 Q2 Quarterly report Financial data

Cover

Cover - shares	6 Months Ended
	Jun. 30, 2022	Aug. 11, 2022
Cover [Abstract]
Document Type	10-Q
Document Quarterly Report	true
Document Period End Date	Jun. 30, 2022
Document Transition Report	false
Entity File Number	001-38241
Entity Registrant Name	OPTINOSE, INC.
Entity Incorporation, State or Country Code	DE
Entity Tax Identification Number	42-1771610
Entity Address, Address Line One	1020 Stony Hill Road
Entity Address, Address Line Two	Suite 300
Entity Address, City or Town	Yardley
Entity Address, State or Province	PA
Entity Address, Postal Zip Code	19067
City Area Code	267
Local Phone Number	364-3500
Title of 12(b) Security	Common stock, par value $0.001 per share
Trading Symbol	OPTN
Security Exchange Name	NASDAQ
Entity Current Reporting Status	Yes
Entity Interactive Data Current	Yes
Entity Filer Category	Non-accelerated Filer
Entity Small Business	true
Entity Emerging Growth Company	true
Entity Ex Transition Period	true
Entity Shell Company	false
Entity Common Stock, Shares Outstanding (in shares)		83,277,504
Entity Central Index Key	0001494650
Current Fiscal Year End Date	--12-31
Document Fiscal Year Focus	2022
Document Fiscal Period Focus	Q2
Amendment Flag	false

Consolidated Balance Sheets

Consolidated Balance Sheets - USD ($) $ in Thousands	Jun. 30, 2022	Dec. 31, 2021
Current assets:
Cash and cash equivalents	$ 78,264	$ 110,502
Accounts receivable, net	25,766	35,449
Inventory	10,973	11,847
Prepaid expenses and other current assets	3,054	2,581
Total current assets	118,057	160,379
Property and equipment, net	1,063	1,347
Other assets	3,712	4,345
Total assets	122,832	166,071
Current liabilities:
Accounts payable	9,829	8,013
Accrued expenses and other current liabilities	45,209	51,222
Total current liabilities	55,038	59,235
Long-term debt, net	127,483	126,418
Other liabilities	1,094	2,190
Total liabilities	183,615	187,843
Stockholders' deficit:
Common stock, $0.001 par value; 200,000,000 shares authorized at June 30, 2022 and December 31, 2021; 83,044,366 and 82,238,900 shares issued and outstanding at June 30, 2022 and December 31, 2021, respectively	83	82
Additional paid-in capital	594,009	588,288
Accumulated deficit	(654,791)	(610,061)
Accumulated other comprehensive loss	(84)	(81)
Total stockholders' deficit	(60,783)	(21,772)
Total liabilities and stockholders' deficit	$ 122,832	$ 166,071

Consolidated Balance Sheets (Pa

Consolidated Balance Sheets (Parenthetical) - $ / shares	Jun. 30, 2022	Dec. 31, 2021
Statement of Financial Position [Abstract]
Common stock, par value (usd per share)	$ 0.001	$ 0.001
Shares authorized (in shares)	200,000,000	200,000,000
Shares issued (in shares)	83,044,366	82,238,900
Shares outstanding (in shares)	83,044,366	82,238,900

Consolidated Statements of Oper

Consolidated Statements of Operations - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2022	Jun. 30, 2021	Jun. 30, 2022	Jun. 30, 2021
Total revenues	$ 20,582	$ 18,357	$ 35,342	$ 30,317
Costs and expenses:
Cost of product sales	2,143	2,425	4,157	4,165
Research and development	4,270	8,179	9,072	13,404
Selling, general and administrative	29,514	27,308	58,853	54,493
Total operating expenses	35,927	37,912	72,082	72,062
Loss from operations	(15,345)	(19,555)	(36,740)	(41,745)
Other (income) expense:
Interest income	(36)	(12)	(170)	(33)
Interest expense	4,086	4,012	8,159	7,888
Foreign currency (gains) losses	2	14	1	22
Gain on sale of property and equipment	0	(67)	0	(67)
Net loss	$ (19,397)	$ (23,502)	$ (44,730)	$ (49,555)
Net loss per share of common stock, basic (in USD per share)	$ (0.23)	$ (0.44)	$ (0.54)	$ (0.93)
Net loss per share of common stock, diluted (in USD per share)	$ (0.23)	$ (0.44)	$ (0.54)	$ (0.93)
Weighted average common shares outstanding, basic (in shares)	82,740,096	53,120,574	82,594,786	53,059,492
Weighted average common shares outstanding, diluted (in shares)	82,740,096	53,120,574	82,594,786	53,059,492
Net product revenues
Total revenues	$ 20,582	$ 18,357	$ 35,342	$ 29,317
Licensing revenues
Total revenues	$ 0	$ 0	$ 0	$ 1,000

Consolidated Statements of Comp

Consolidated Statements of Comprehensive Loss - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2022	Jun. 30, 2021	Jun. 30, 2022	Jun. 30, 2021
Statement of Comprehensive Income [Abstract]
Net loss	$ (19,397)	$ (23,502)	$ (44,730)	$ (49,555)
Other comprehensive loss:
Foreign currency translation adjustment	(2)	0	(3)	2
Comprehensive loss	$ (19,399)	$ (23,502)	$ (44,733)	$ (49,553)

Consolidated Statements of Chan

Consolidated Statements of Changes in Stockholders' Equity (Deficit) - USD ($) $ in Thousands	Total	Common Stock	Additional Paid-in Capital	Accumulated Deficit	Accumulated Other Comprehensive Loss
Beginning balance (in shares) at Dec. 31, 2020		52,945,865
Beginning balance at Dec. 31, 2020	$ 6,788	$ 53	$ 534,585	$ (527,765)	$ (85)
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Stock compensation expense	$ 2,596		2,596
Vesting of restricted stock units (in shares)	0	166,709
Foreign currency translation adjustment	$ 2				2
Net loss	(26,053)			(26,053)
Ending balance (in shares) at Mar. 31, 2021		53,112,574
Ending balance at Mar. 31, 2021	(16,667)	$ 53	537,181	(553,818)	(83)
Beginning balance (in shares) at Dec. 31, 2020		52,945,865
Beginning balance at Dec. 31, 2020	6,788	$ 53	534,585	(527,765)	(85)
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Net loss	(49,555)
Ending balance (in shares) at Jun. 30, 2021		53,285,133
Ending balance at Jun. 30, 2021	(37,073)	$ 53	540,277	(577,320)	(83)
Beginning balance (in shares) at Mar. 31, 2021		53,112,574
Beginning balance at Mar. 31, 2021	(16,667)	$ 53	537,181	(553,818)	(83)
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Stock compensation expense	$ 2,729		2,729
Vesting of restricted stock units (in shares)	0	37,034
Issuance of common stock under employee stock purchase plan (in shares)		135,525
Issuance of common stock under employee stock purchase plan	$ 367	$ 0	367
Foreign currency translation adjustment	0				0
Net loss	(23,502)			(23,502)
Ending balance (in shares) at Jun. 30, 2021		53,285,133
Ending balance at Jun. 30, 2021	(37,073)	$ 53	540,277	(577,320)	(83)
Beginning balance (in shares) at Dec. 31, 2021		82,238,900
Beginning balance at Dec. 31, 2021	(21,772)	$ 82	588,288	(610,061)	(81)
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Stock compensation expense	$ 1,998		1,998
Vesting of restricted stock units (in shares)	0	262,942
Issuance of common stock under employee stock purchase plan (in shares)		179,206
Issuance of common stock under employee stock purchase plan	$ 250	$ 1	249
Foreign currency translation adjustment	(1)				(1)
Net loss	(25,333)			(25,333)
Ending balance (in shares) at Mar. 31, 2022		82,681,048
Ending balance at Mar. 31, 2022	(44,858)	$ 83	590,535	(635,394)	(82)
Beginning balance (in shares) at Dec. 31, 2021		82,238,900
Beginning balance at Dec. 31, 2021	(21,772)	$ 82	588,288	(610,061)	(81)
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Net loss	(44,730)
Ending balance (in shares) at Jun. 30, 2022		83,044,366
Ending balance at Jun. 30, 2022	(60,783)	$ 83	594,009	(654,791)	(84)
Beginning balance (in shares) at Mar. 31, 2022		82,681,048
Beginning balance at Mar. 31, 2022	(44,858)	$ 83	590,535	(635,394)	(82)
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Stock compensation expense	3,474		3,474
Vesting of restricted stock units (in shares)		363,318
Vesting of restricted stock units and exercise of options	0		0
Foreign currency translation adjustment	(2)				(2)
Net loss	(19,397)			(19,397)
Ending balance (in shares) at Jun. 30, 2022		83,044,366
Ending balance at Jun. 30, 2022	$ (60,783)	$ 83	$ 594,009	$ (654,791)	$ (84)

Consolidated Statements of Cash

Consolidated Statements of Cash Flows - USD ($) $ in Thousands	6 Months Ended
	Jun. 30, 2022	Jun. 30, 2021
Operating activities:
Net loss	$ (44,730)	$ (49,555)
Adjustments to reconcile net loss to cash used in operating activities:
Depreciation and amortization	256	324
Stock-based compensation	5,444	5,343
Amortization of debt discount and issuance costs	1,065	861
Gain on sale of property and equipment	0	(67)
Changes in operating assets and liabilities:
Accounts receivable	9,683	2,679
Prepaid expenses and other assets	446	451
Inventory	950	(4,218)
Accounts payable	1,810	(1,900)
Accrued expenses and other liabilities	(7,397)	(4,436)
Cash used in operating activities	(32,473)	(50,518)
Investing activities:
Purchases of property and equipment	(50)	(115)
Proceeds from sale of property and equipment	0	105
Cash used in investing activities	(50)	(10)
Financing activities:
Cash paid for financing costs	27	(91)
Proceeds from issuance of common stock under employee stock purchase plan	249	367
Cash provided by financing activities	276	276
Effects of exchange rate changes on cash and cash equivalents	3	0
Net decrease in cash, cash equivalents and restricted cash	(32,244)	(50,252)
Cash, cash equivalents and restricted cash at beginning of period	110,515	144,179
Cash, cash equivalents and restricted cash at end of period	78,271	93,927
Supplemental disclosure of noncash activities:
Fixed asset purchases within accounts payable and accrued expenses	18	23
Recognition of right-of-use assets	287	157
Recognition of lease liabilities	$ 287	$ 157

Organization and Description of

Organization and Description of Business	6 Months Ended
	Jun. 30, 2022
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Organization and Description of Business	Organization and Description of Business OptiNose, Inc. (the Company) was incorporated in Delaware in May 2010 (inception) and has facilities in Yardley, Pennsylvania, Ewing, New Jersey, and Oslo, Norway. The Company's predecessor entity, OptiNose AS, was formed under the laws of Norway in September 2000. In 2010, OptiNose AS became a wholly-owned subsidiary of the Company as part of an internal reorganization. During 2022, the Company’s board of directors approved the liquidation of Optinose AS and Optinose UK in order to simplify corporate structure. The Company is a specialty pharmaceutical company focused on the development and commercialization of products for patients treated by ear, nose and throat (ENT) and allergy specialists. The Company's first commercial product, XHANCE ® (fluticasone propionate) nasal spray, 93 mcg, is a therapeutic utilizing its proprietary Exhalation Delivery System (EDS) that delivers a topically-acting corticosteroid for the treatment of chronic rhinosinusitis with nasal polyps and, if approved, chronic rhinosinusitis without nasal polyps (also referred to as chronic sinusitis). XHANCE was approved by the United States (US) Food and Drug Administration (FDA) in September 2017 for the treatment of nasal polyps in patients 18 years of age or older. XHANCE was made widely available through commercial channels in April 2018.

Liquidity

Liquidity	6 Months Ended
	Jun. 30, 2022
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Liquidity	Liquidity Since inception, the Company's operations have focused on organization and staffing, business planning, raising capital, establishing an intellectual property portfolio, conducting preclinical studies and clinical trials, pursuing regulatory approvals and most recently, commercializing XHANCE in the US. As of June 30, 2022, the Company had cash and cash equivalents of $78,264. For the six months ended June 30, 2022, the Company had a net loss of $44,730 and negative cash from operations of $32,473. As of June 30, 2022, the Company had an accumulated deficit of $654,791. The Company will likely require additional capital in the future secured through equity or debt financings, partnerships, collaborations, or other sources in order to meet its debt service obligations, including repayment, under the Company's outstanding senior secured notes, and to carry out the Company's planned development and commercial activities. The terms of the outstanding senior secured notes, including applicable covenants, are described in Note 8. If additional capital is not obtained when required, the Company may need to delay or curtail its operations until additional funding is received. The Company is subject to a number of risks similar to other life sciences companies, including, but not limited to, successful discovery, development and commercialization of its products and product candidates, raising additional capital, the development by its competitors of new technological innovations, protection of proprietary technology and market acceptance of the Company's products.

Basis of Presentation and Summa

Basis of Presentation and Summary of Significant Accounting Policies	6 Months Ended
	Jun. 30, 2022
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Basis of Presentation and Summary of Significant Accounting Policies	Basis of Presentation and Summary of Significant Accounting Policies The accompanying unaudited interim consolidated financial statements have been prepared in conformity with US generally accepted accounting principles (GAAP). Any reference in these notes to applicable guidance is meant to refer to GAAP as found in the Accounting Standards Codification (ASC) and Accounting Standards Updates (ASU) of the Financial Accounting Standards Board (FASB). In the opinion of management, the accompanying unaudited interim financial statements include all normal and recurring adjustments (which consist primarily of accruals and estimates that impact the financial statements) considered necessary to present fairly the Company's financial position as of June 30, 2022 and its results of operations for the three and six months ended June 30, 2022 and 2021 and cash flows for the six months ended June 30, 2022 and 2021. Operating results for the three and six months ended June 30, 2022 are not necessarily indicative of the results that may be expected for the year ending December 31, 2022. The unaudited interim financial statements, presented herein, do not contain the required disclosures under GAAP for annual financial statements. The accompanying unaudited interim financial statements should be read in conjunction with the annual audited financial statements and related notes as of and for the year ended December 31, 2021 contained in the Company’s annual report on Form 10-K for the year ended December 31, 2021 , filed with the SEC on March 8, 2022. Use of estimates The preparation of the unaudited interim consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the unaudited interim consolidated financial statements and reported amounts of expenses during the reporting period. Due to the uncertainty of factors surrounding the estimates or judgments used in the preparation of the unaudited interim consolidated financial statements, actual results may materially vary from these estimates. Estimates and assumptions are periodically reviewed and the effects of revisions are reflected in the unaudited interim consolidated financial statements in the period they are determined to be necessary. Concentration of credit risk Financial instruments that potentially subject the Company to concentrations of credit risk are primarily cash and accounts receivable. The Company generally invests its cash in deposits with high credit quality financial institutions. Additionally, the Company performs periodic evaluations of the relative credit standing of these financial institutions. Customer and supplier concentration The Company has exposure to credit risk in accounts receivable from sales of product. XHANCE is sold to wholesale pharmaceutical distributors and preferred pharmacy network (PPN) partners, who, in turn, sell XHANCE to pharmacies, hospitals and other customers. Five customers represented approximately 40% of the Company's accounts receivable at June 30, 2022 and five customers represented approximately 26% and 29% of the Company's net product sales for the three and six months ended June 30, 2022. The Company purchases XHANCE and its components from several third-party suppliers and manufacturing partners, certain of which are available through a single source. Although the Company could obtain each of these components from alternative third-party suppliers, it would need to qualify and obtain FDA approval for another supplier as a source for each such component. The Company has initiated the process of qualifying an alternate third-party supplier for select components of XHANCE. Alternate third party suppliers of XHANCE components are subject to qualification and approval from the FDA. Fair value of financial instruments At June 30, 2022 and December 31, 2021, the Company's financial instruments included cash and cash equivalents, accounts receivable, grants receivable, accounts payable and accrued expenses. The carrying amounts reported in the Company's financial statements for these instruments approximate their respective fair values because of the short-term nature of these instruments. In addition, the Company believes that at June 30, 2022, the carrying value of long-term debt approximated fair value as the interest rates are reflective of the rate the Company could obtain on debt with similar terms and conditions. At June 30, 2022 and December 31, 2021, there were no financial assets or liabilities measured at fair value on a recurring basis. Restricted cash As of June 30, 2022 and December 31, 2021, the restricted cash balance included in prepaid expenses and other assets was $7 and $13, respectively. Net product revenues The Company accounts for revenue in accordance with ASC Topic 606, Revenue from Contracts with Customers (ASC 606), which the Company adopted on January 1, 2018. The Company recognizes revenue from XHANCE sales at the point customers obtain control of the product, which generally occurs upon delivery. The transaction price that is recognized as revenue for products includes an estimate of variable consideration. The Company’s estimates of variable consideration and determination of whether to include estimated amounts in the transaction price are based largely on an assessment of its anticipated performance and all information (historical, current and forecasted) that is reasonably available. The components of the Company’s variable consideration include the following: Provider Chargebacks and Discounts. Chargebacks for fees and discounts to providers represent the estimated obligations resulting from contractual commitments to sell products to qualified healthcare providers at prices lower than the list prices charged to customers who directly purchase the product from the Company. Customers charge the Company for the difference between what they pay for the product and the ultimate selling price to the qualified healthcare providers. These components of variable consideration are established in the same period that the related revenue is recognized, resulting in a reduction of product revenue and accounts receivable. Trade Discounts and Allowances. The Company generally provides customers with discounts that include incentive fees which are explicitly stated in the Company’s contracts. These discounts are recorded as a reduction of revenue and accounts receivable in the period in which the related product revenue is recognized. Product Returns. Consistent with industry practice, the Company has a product returns policy that provides customers a right of return for product purchased within a specified period prior to and subsequent to the product’s expiration date. The Company estimates the amount of its product that may be returned and presents this amount as a reduction of revenue in the period the related product revenue is recognized, in addition to establishing a liability. The Company considers several factors in the estimation process, including expiration dates of product shipped to customers, inventory levels within the distribution channel, product shelf life, prescription trends and other relevant factors. Government Rebates. The Company is subject to discount obligations under state Medicaid programs and Medicare. Reserves related to these discount obligations are recorded in the same period the related revenue is recognized, resulting in a reduction of product revenue and the establishment of a current liability. The Company’s liability for these rebates consists of estimates of claims for the current quarter and estimated future claims that will be made for product that has been recognized as revenue but remains in the distribution channel inventories at the end of the reporting period. Payor Rebates. The Company contracts with certain third-party payors, primarily health insurance companies and pharmacy benefit managers, for the payment of rebates with respect to utilization of its products. These rebates are based on contractual percentages applied to the amount of product prescribed to patients who are covered by the plan or the organization with which it contracts. The Company estimates these rebates and records such estimates in the same period the related revenue is recognized, resulting in a reduction of product revenue and the establishment of a current liability. Patient Assistance. Other programs that the Company offers include voluntary co-pay patient assistance programs intended to provide financial assistance to eligible patients with prescription drug co-payments required by payors and coupon programs for cash payors. The calculation of the current liability for this assistance is based on an estimate of claims and the cost per claim that the Company expects to receive associated with product that has been recognized as revenue but remains in the distribution channel inventories at the end of each reporting period. Distribution and Other Fees . The Company pays distribution and other fees to certain customers in connection with the sales of its products. The Company records distribution and other fees paid to its customers as a reduction of revenue, unless the payment is for a distinct good or service from the customer and the Company can reasonably estimate the fair value of the goods or services received. If both conditions are met, the Company records the consideration paid to the customer as an operating expense. These costs are typically known at the time of sale, resulting in minimal adjustments subsequent to the period of sale. Licensing revenues The Company has license agreements with Centessa Pharmaceuticals (Centessa) and Currax Pharmaceuticals LLC (Currax). These license agreements provide for exclusive licensed rights to certain intellectual property, a non-refundable up-front payment, potential milestone payment(s) and potential royalty payment(s). The Company analyzed the performance obligations under the license agreements, the consideration received to date and the consideration the Company could receive in the future as part of its analysis related to ASC 606. The Company is not eligible to receive any further payments under the Currax license agreement other than reimbursement for certain expenses. The Company does not expect to any receive license revenues under the Centessa agreement in the near term. Net income (loss) per common share Basic net income (loss) per common share is determined by dividing net income (loss) applicable to Company common stock (Common Stock) holders by the weighted average common shares outstanding during the period. For the three and six months ended June 30, 2022 and 2021, the outstanding Common Stock options, Restricted Stock units, Common Stock warrants and shares to be issued under the Company's 2017 Employee Stock Purchase Plan have been excluded from the calculation of diluted net loss per share because their effect would be anti-dilutive. Therefore, the weighted average shares used to calculate both basic and diluted net loss per share are the same. Diluted net loss per common share for the periods presented do not reflect the following potential common shares, as the effect would be antidilutive: June 30, 2022 2021 Stock options 10,235,914 7,980,424 Restricted stock units 2,201,683 2,198,766 Common stock warrants 2,500,000 810,357 Employee stock purchase plan 208,138 — Total 15,145,735 10,989,547 Income taxes In accordance with ASC 270, Interim Reporting , and ASC 740, Income Taxes , the Company is required at the end of each interim period to determine the best estimate of its annual effective tax rate and then apply that rate in providing for income taxes on a current year-to-date (interim period) basis. For the three and six months ended June 30, 2022 and 2021, the Company recorded no tax expense or benefit due to the expected current year loss and its historical losses. As of June 30, 2022 and December 31, 2021, the Company concluded that a full valuation allowance would be necessary for all of its net deferred tax assets. The Company had no amounts recorded for uncertain tax positions, interest or penalties in the accompanying consolidated financial statements.

Inventory

Inventory	6 Months Ended
	Jun. 30, 2022
Inventory Disclosure [Abstract]
Inventory	Inventory Inventory consisted of the following: June 30, 2022 December 31, 2021 Raw materials $ 2,508 $ 3,504 Work-in-process 5,989 4,816 Finished goods 2,476 3,527 Total inventory $ 10,973 $ 11,847

Property and Equipment

Property and Equipment	6 Months Ended
	Jun. 30, 2022
Property, Plant and Equipment [Abstract]
Property and Equipment	Property and Equipment Property and equipment, net, consisted of the following: June 30, 2022 December 31, 2021 Computer equipment and software $ 1,199 $ 1,173 Furniture and fixtures 366 366 Machinery and equipment 3,061 3,367 Leasehold improvements 609 609 Construction in process 115 115 5,350 5,630 Less: accumulated depreciation (4,287) (4,283) $ 1,063 $ 1,347 Depreciation expense was $137 and $119 for the three months ended June 30, 2022 and 2021, respectively. Depreciation expense was $255 and $323 for the six months ended June 30, 2022 and 2021, respectively. In addition, depreciation expense of $651 and $10 was charged to inventory and prepaid expenses and other assets, respectively, as of June 30, 2022, which represents depreciation expense related to equipment involved in the manufacturing process.

Accrued Expenses and Other Curr

Accrued Expenses and Other Current Liabilities	6 Months Ended
	Jun. 30, 2022
Payables and Accruals [Abstract]
Accrued Expenses and Other Current Liabilities	Accrued Expenses and Other Current Liabilities Accrued expenses and other current liabilities consisted of: June 30, 2022 December 31, 2021 Accrued expenses: Selling, general and administrative expenses $ 7,016 $ 6,124 Research and development expenses 3,086 6,857 Payroll expenses 7,332 7,569 Product revenue allowances 23,126 26,521 Other 2,293 2,057 Total accrued expenses 42,853 49,128 Other current liabilities: Lease liability 2,356 2,094 Total other current liabilities 2,356 2,094 Total accrued expenses and other current liabilities $ 45,209 $ 51,222

Licensing Revenue

Licensing Revenue	6 Months Ended
	Jun. 30, 2022
Research and Development [Abstract]
Licensing Revenue	Licensing Revenue Currax License Agreement On September 25, 2019, OptiNose AS entered into a license agreement (the Currax License Agreement) with Currax pursuant to which the Company granted Currax a license to certain intellectual property for the commercialization of Onzetra Xsail ® in the US, Canada and Mexico. Under the terms of the Currax License Agreement, Currax paid the Company an upfront payment of $3,730, which was recognized as license revenue during the year ended December 31, 2019. On December 29, 2020, the Company received an additional $750 upon the expiration of the escrow that was established for a limited period to cover potential indemnification obligations. In addition, in January 2021 the Company received a $1,000 milestone payment in connection with the achievement of a specified regulatory milestone. The Company is no longer eligible to receive any further payments from Currax under the terms of the Currax License Agreement other than reimbursement for certain expenses.

Long-term Debt

Long-term Debt	6 Months Ended
	Jun. 30, 2022
Debt Disclosure [Abstract]
Long-term Debt	Long-term Debt On September 12, 2019 (the Closing Date), the Company entered into a Note Purchase Agreement with funds managed by Pharmakon Advisors, LP (Pharmakon), the investment manager of BioPharma Credit Funds (BioPharma). The Note Purchase Agreement provided the Issuer with $130,000 in debt financing, of which $80,000 of Pharmakon Senior Secured Notes was issued on the Closing Date, $30,000 was issued on February 13, 2020 after achieving the $9,000 consolidated XHANCE net sales and royalties threshold for the quarter ended December 31, 2019 and $20,000 was issued on December 1, 2020 after achieving the $14,500 consolidated XHANCE net sales and royalties threshold for the quarter ended September 30, 2020. The Pharmakon Senior Secured Notes bear interest at a fixed rate of 10.75% per annum and are scheduled to mature on September 12, 2024 (the Maturity Date). Principal repayments will commence on September 15, 2023, with five The Issuer is required to repay the Pharmakon Senior Secured Notes in full upon the occurrence of a change of control (as defined in the Note Purchase Agreement). In addition, the Issuer may make voluntary prepayments in whole or in part. All mandatory and voluntary prepayments are subject to the payment of prepayment premiums as follows: (i) if prepayment occurs prior to the third anniversary of the Closing Date, an amount equal to 2% of the principal prepaid, (ii) if prepayment occurs on or after the third anniversary of the Closing Date but prior to the fourth anniversary of the Closing Date, an amount equal to 1% of the principal prepaid, and (iii) if prepayment occurs on or after the fourth anniversary of the Closing Date, no prepayment premium is required. The Company is also required to pay a "make-whole" amount in respect of any principal prepayments (whether mandatory or voluntary) made prior to the 30-month anniversary of the closing of the Company's underwritten public offering on November 18, 2021, in an amount equal to the interest that would have accrued through the 30-month anniversary in respect of such note but for such principal prepayment, provided that in the case of any prepayment made prior to the 15-month anniversary, the Company will not be required to pay a "make-whole" amount in excess of an amount equal to the interest that would have accrued through the 15-month anniversary but for such principal prepayment. The Pharmakon Senior Secured Notes are secured by a pledge of substantially all of the assets of the Issuer and the Guarantors and the Note Purchase Agreement contains affirmative and negative covenants customary for financings of this type, including limitations on the Company’s and its subsidiaries’ ability, among other things, to incur additional debt, grant or permit additional liens, make investments and acquisitions, merge or consolidate with others, dispose of assets, pay dividends and distributions, repay junior indebtedness and enter into affiliate transactions, in each case, subject to certain exceptions. In addition, the Note Purchase Agreement contains financial covenants requiring the Company to maintain at all times certain minimum trailing twelve-month consolidated XHANCE net sales and royalties, tested on a quarterly basis, and at least $30,000 of cash and cash equivalents. As of June 30, 2022, the Company was in compliance with the covenants. The Note Purchase Agreement also includes events of default customary for financings of this type, in certain cases subject to customary periods to cure, following which BioPharma may accelerate all amounts outstanding under the Pharmakon Senior Secured Notes. The Company recorded interest expense of $4,086 and $4,012 during the three months ended June 30, 2022 and 2021, respectively, and $8,159 and $7,888 during the six months ended June 30, 2022 and 2021, respectively. Interest expense included total coupon interest and the amortization of debt issuance costs. The long-term debt balance is comprised of the following: June 30, 2022 December 31, 2021 Face amount $ 130,000 $ 130,000 Front end fees (559) (717) Debt issuance costs (3,258) (4,165) Back end fees 1,300 1,300 Long-term debt, net $ 127,483 $ 126,418

Employee Benefit Plans

Employee Benefit Plans	6 Months Ended
	Jun. 30, 2022
Retirement Benefits [Abstract]
Employee Benefit Plans	Employee Benefit Plans For US employees, the Company maintains a defined contribution 401(k) retirement plan. As of June 30, 2022, $91 was recorded in accrued liabilities related to the Company match. The Company's contributions are made in cash. For foreign employees, the Company maintains a defined contribution pension plan which meets the statutory requirements of the jurisdiction. The Company incurred costs related to the pension plan of $2 and $1 for the three months ended June 30, 2022 and 2021, respectively, and $3 and $3 for the six months ended June 30, 2022 and 2021, respectively.

Stockholders' Equity

Stockholders' Equity	6 Months Ended
	Jun. 30, 2022
Equity [Abstract]
Stockholders' Equity	Stockholders' Equity Common stock warrants On November 18, 2021, in conjunction with the Second Amendment to the Note Purchase Agreement (the Second Amendment), the Company issued warrants to purchase an aggregate of 2,500,000 shares of Common Stock at an exercise price of $1.60 and fair value of $2,009. Upon execution of the Second Amendment, warrants previously issued of 810,357 at a share price of $6.72 which were set to expire on September 12, 2022, were cancelled. As of June 30, 2022, the Company had the following warrants outstanding to purchase shares of Common Stock: Number of Shares Exercise Price Per Share Expiration Date 2,500,000 $1.60 November 18, 2024

Stock-based Compensation

Stock-based Compensation	6 Months Ended
	Jun. 30, 2022
Share-Based Payment Arrangement [Abstract]
Stock-based Compensation	Stock-based Compensation The Company recorded stock-based compensation expense related to stock options and shares issued under the Company's 2010 Stock Incentive Plan and 2017 Employee Stock Purchase Plan (2017 Plan) in the following expense categories of its accompanying consolidated statements of operations for the three and six months ended June 30, 2022 and 2021: Three Months Ended Six Months Ended 2022 2021 2022 2021 Cost of product sales $ 7 $ 6 $ 20 $ 17 Research and development 233 286 429 567 General and administrative 3,204 2,441 4,995 4,759 $ 3,444 $ 2,733 $ 5,444 $ 5,343 In addition, stock-based compensation expense of $85 and $1 was charged to inventory and prepaid expenses and other assets, respectively, during the six months ended June 30, 2022, which represents the total stock-based compensation expense incurred related to employees involved in the manufacturing process of finished goods and samples during the period. Stock Options The Company issues stock-based awards pursuant to its 2010 Stock Incentive Plan. Effective as of October 12, 2017, the Company's 2010 Stock Incentive Plan was amended and restated (A&R Plan).The Company has issued service-based, performance-based, and market-based stock options that generally have a contractual life of up to 10 years and may be exercisable in cash or as otherwise determined by the Company's board of directors or committee thereof. Vesting generally occurs over a period of not greater than four years. Performance-based options may vest upon the achievement of certain milestones. As of June 30, 2022, all of the performance conditions related to performance-based stock options issued by the Company had been achieved. Market-based options may vest upon the achievement of certain market-based objectives relating to the trading price of the Common Stock. The following table summarizes the activity related to stock option grants to employees and non-employees for the six months ended June 30, 2022: Shares Weighted Weighted Outstanding at December 31, 2021 7,958,781 $ 8.87 6.50 Granted 2,902,370 1.88 Exercised (67,125) 1.63 Expired (135,983) 8.89 Forfeited (422,129) 3.86 Outstanding at June 30, 2022 10,235,914 $ 7.65 6.62 Exercisable at June 30, 2022 5,819,746 $ 10.37 5.26 Vested and expected to vest at June 30, 2022 9,342,884 $ 7.65 6.62 During the six months ended June 30, 2022, stock options to purchase 2,902,370 shares of Common Stock were granted to employees and generally vest over four years. Included in the total stock options granted were market-based options to purchase 959,215 shares of Common Stock. The stock options, including the market-based options, had an estimated weighted average grant date fair value of $1.19. During the six months ended June 30, 2021, stock options to purchase 1,542,696 shares of Common Stock were granted to employees that generally vest over four years. The stock options had an estimated weighted average grant date fair value of $2.29. The grant date fair value of each stock option grant, other than market-based stock option grants, was estimated at the time of grant using the Black-Scholes option-pricing model using the following weighted average assumptions: Six Months Ended June 30, 2022 2021 Risk free interest rate 1.82 % 1.00 % Expected term (in years) 6.08 6.08 Expected volatility 72.67 % 74.28 % Annual dividend yield 0.00 % 0.00 % Fair value of common stock $ 1.90 $ 3.52 At June 30, 2022, the unrecognized compensation cost related to unvested stock options, other than market-based stock options, expected to vest was $6,655. This unrecognized compensation will be recognized over an estimated weighted-average amortization period of 2.28 years. During the six months ended June 30, 2022, market-based options to purchase 959,215 shares of Common Stock were granted to employees and generally become eligible to vest over four years, subject to the achievement of certain market-based objectives relating to the trading price of the Common Stock. Stock based compensation for these awards is recognized over the derived service period of approximately 2 years. The grant date fair value of each stock option grant, as well as the derived service period for these awards, was estimated at the time of grant using a Monte Carlo simulation based on the following assumptions: Six Months Ended 2022 Risk free rates of return 1.70 % Expected volatility 75.00 % Annual dividend yield — % Restricted Stock Units The Company has issued service-based and performance-based restricted stock units (RSUs). Vesting generally occurs over a period not greater than four years. Vesting of the performance-based RSUs is subject to the achievement of certain milestones in connection with the Company's development programs. The following table summarizes the activity related to RSUs granted to employees for the six months ended June 30, 2022: Shares Outstanding at December 31, 2021 1,959,358 Granted 1,105,246 Vested and settled (598,775) Expired/forfeited/canceled (264,146) Outstanding at June 30, 2022 2,201,683 Expected to vest at June 30, 2022 2,201,683 During the six months ended June 30, 2022, the Company granted 1,105,246 RSUs at a grant date fair value of $1.85, all of which were service-based RSUs. No performance-based RSUs were granted in 2022. As of June 30, 2022, one of the milestones associated with the previously granted performance based-RSUs was achieved. As a result 248,830 RSUs vested on June 15, 2022 and stock based compensation expense of $1,346 was recognized for these awards. At June 30, 2022, the unrecognized compensation cost related to unvested service-based RSUs expected to vest was $5,041, to be recognized over an estimated weighted-average amortization period of 2.63 years. The unrecognized compensation cost related to unvested performance-based RSUs was $1,749, which will be recognized over the remaining service period. Included in the table above are 60,000 RSUs granted outside the A&R Plan. The grants were made pursuant to the Nasdaq inducement grant exception in accordance with Nasdaq Listing Rule 5635(c)(4). 2017 Employee Stock Purchase Plan Under the 2017 Plan, shares of Common Stock may be purchased by eligible employees who elect to participate in the 2017 Plan at 85% of the lower of the fair market value of Common Stock on the first or last day of designated offering periods. The Company recognized stock-based compensation expense of $74 and $91 during the three months ended June 30, 2022 and 2021, respectively, and $162 and $199 during the six months ended June 30, 2022 and 2021, respectively, related to the 2017 Plan. The Company calculated the fair value of each option grant and the shares issued under the 2017 Plan on the respective dates of grant using the following weighted average assumptions: Six Months Ended June 30, 2022 2021 Risk free interest rate 0.22 % 0.09 % Expected term (in years) 0.5 0.5 Expected volatility 88.56 % 86.88 % Annual dividend yield 0.00 % 0.00 %

Subsequent Events

Subsequent Events	6 Months Ended
	Jun. 30, 2022
Subsequent Events [Abstract]
Subsequent Events	Subsequent Events On August 10, 2022, the Company entered into a Third Amendment to the Note Purchase Agreement (the Third Amendment). The Third Amendment reduced the minimum c onsolidated XHANCE net sales and royalties required to be achieved under the Note Purchase Agreement for the trailing twelve-month period ending December 31, 2022 from $90,000 to $85,000 in exchange for a $780 fee due on the repayment of the Pharmakon Senior Secured Notes.

Basis of Presentation and Sum_2

Basis of Presentation and Summary of Significant Accounting Policies (Policies)	6 Months Ended
	Jun. 30, 2022
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Use of estimates	Use of estimates The preparation of the unaudited interim consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the unaudited interim consolidated financial statements and reported amounts of expenses during the reporting period. Due to the uncertainty of factors surrounding the estimates or judgments used in the preparation of the unaudited interim consolidated financial statements, actual results may materially vary from these estimates. Estimates and assumptions are periodically reviewed and the effects of revisions are reflected in the unaudited interim consolidated financial statements in the period they are determined to be necessary.
Concentration of credit risk and customer and supplier concentration	Concentration of credit risk Financial instruments that potentially subject the Company to concentrations of credit risk are primarily cash and accounts receivable. The Company generally invests its cash in deposits with high credit quality financial institutions. Additionally, the Company performs periodic evaluations of the relative credit standing of these financial institutions. Customer and supplier concentration
Fair value of financial instruments	Fair value of financial instrumentsAt June 30, 2022 and December 31, 2021, the Company's financial instruments included cash and cash equivalents, accounts receivable, grants receivable, accounts payable and accrued expenses. The carrying amounts reported in the Company's financial statements for these instruments approximate their respective fair values because of the short-term nature of these instruments. In addition, the Company believes that at June 30, 2022, the carrying value of long-term debt approximated fair value as the interest rates are reflective of the rate the Company could obtain on debt with similar terms and conditions.
Restricted cash	Restricted cashAs of June 30, 2022 and December 31, 2021, the restricted cash balance included in prepaid expenses and other assets was $7 and $13, respectively.
Net product revenues and licensing revenues	Net product revenues The Company accounts for revenue in accordance with ASC Topic 606, Revenue from Contracts with Customers (ASC 606), which the Company adopted on January 1, 2018. The Company recognizes revenue from XHANCE sales at the point customers obtain control of the product, which generally occurs upon delivery. The transaction price that is recognized as revenue for products includes an estimate of variable consideration. The Company’s estimates of variable consideration and determination of whether to include estimated amounts in the transaction price are based largely on an assessment of its anticipated performance and all information (historical, current and forecasted) that is reasonably available. The components of the Company’s variable consideration include the following: Provider Chargebacks and Discounts. Chargebacks for fees and discounts to providers represent the estimated obligations resulting from contractual commitments to sell products to qualified healthcare providers at prices lower than the list prices charged to customers who directly purchase the product from the Company. Customers charge the Company for the difference between what they pay for the product and the ultimate selling price to the qualified healthcare providers. These components of variable consideration are established in the same period that the related revenue is recognized, resulting in a reduction of product revenue and accounts receivable. Trade Discounts and Allowances. The Company generally provides customers with discounts that include incentive fees which are explicitly stated in the Company’s contracts. These discounts are recorded as a reduction of revenue and accounts receivable in the period in which the related product revenue is recognized. Product Returns. Consistent with industry practice, the Company has a product returns policy that provides customers a right of return for product purchased within a specified period prior to and subsequent to the product’s expiration date. The Company estimates the amount of its product that may be returned and presents this amount as a reduction of revenue in the period the related product revenue is recognized, in addition to establishing a liability. The Company considers several factors in the estimation process, including expiration dates of product shipped to customers, inventory levels within the distribution channel, product shelf life, prescription trends and other relevant factors. Government Rebates. The Company is subject to discount obligations under state Medicaid programs and Medicare. Reserves related to these discount obligations are recorded in the same period the related revenue is recognized, resulting in a reduction of product revenue and the establishment of a current liability. The Company’s liability for these rebates consists of estimates of claims for the current quarter and estimated future claims that will be made for product that has been recognized as revenue but remains in the distribution channel inventories at the end of the reporting period. Payor Rebates. The Company contracts with certain third-party payors, primarily health insurance companies and pharmacy benefit managers, for the payment of rebates with respect to utilization of its products. These rebates are based on contractual percentages applied to the amount of product prescribed to patients who are covered by the plan or the organization with which it contracts. The Company estimates these rebates and records such estimates in the same period the related revenue is recognized, resulting in a reduction of product revenue and the establishment of a current liability. Patient Assistance. Other programs that the Company offers include voluntary co-pay patient assistance programs intended to provide financial assistance to eligible patients with prescription drug co-payments required by payors and coupon programs for cash payors. The calculation of the current liability for this assistance is based on an estimate of claims and the cost per claim that the Company expects to receive associated with product that has been recognized as revenue but remains in the distribution channel inventories at the end of each reporting period. Distribution and Other Fees . The Company pays distribution and other fees to certain customers in connection with the sales of its products. The Company records distribution and other fees paid to its customers as a reduction of revenue, unless the payment is for a distinct good or service from the customer and the Company can reasonably estimate the fair value of the goods or services received. If both conditions are met, the Company records the consideration paid to the customer as an operating expense. These costs are typically known at the time of sale, resulting in minimal adjustments subsequent to the period of sale. Licensing revenues
Net income (loss) per common share	Net income (loss) per common shareBasic net income (loss) per common share is determined by dividing net income (loss) applicable to Company common stock (Common Stock) holders by the weighted average common shares outstanding during the period. For the three and six months ended June 30, 2022 and 2021, the outstanding Common Stock options, Restricted Stock units, Common Stock warrants and shares to be issued under the Company's 2017 Employee Stock Purchase Plan have been excluded from the calculation of diluted net loss per share because their effect would be anti-dilutive. Therefore, the weighted average shares used to calculate both basic and diluted net loss per share are the same.
Income taxes	Income taxes In accordance with ASC 270, Interim Reporting , and ASC 740, Income Taxes , the Company is required at the end of each interim period to determine the best estimate of its annual effective tax rate and then apply that rate in providing for income taxes on a current year-to-date (interim period) basis. For the three and six months ended June 30, 2022 and 2021, the Company recorded no tax expense or benefit due to the expected current year loss and its historical losses. As of June 30, 2022 and December 31, 2021, the Company concluded that a full valuation allowance would be necessary for all of its net deferred tax assets. The Company had no amounts recorded for uncertain tax positions, interest or penalties in the accompanying consolidated financial statements.

Basis of Presentation and Sum_3

Basis of Presentation and Summary of Significant Accounting Policies (Tables)	6 Months Ended
	Jun. 30, 2022
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Schedule of Antidilutive Shares Excluded From Computation of Net Loss Per Common Share	Diluted net loss per common share for the periods presented do not reflect the following potential common shares, as the effect would be antidilutive: June 30, 2022 2021 Stock options 10,235,914 7,980,424 Restricted stock units 2,201,683 2,198,766 Common stock warrants 2,500,000 810,357 Employee stock purchase plan 208,138 — Total 15,145,735 10,989,547

Inventory (Tables)

Inventory (Tables)	6 Months Ended
	Jun. 30, 2022
Inventory Disclosure [Abstract]
Schedule of Inventory	Inventory consisted of the following: June 30, 2022 December 31, 2021 Raw materials $ 2,508 $ 3,504 Work-in-process 5,989 4,816 Finished goods 2,476 3,527 Total inventory $ 10,973 $ 11,847

Property and Equipment (Tables)

Property and Equipment (Tables)	6 Months Ended
	Jun. 30, 2022
Property, Plant and Equipment [Abstract]
Schedule of Property and Equipment	Property and equipment, net, consisted of the following: June 30, 2022 December 31, 2021 Computer equipment and software $ 1,199 $ 1,173 Furniture and fixtures 366 366 Machinery and equipment 3,061 3,367 Leasehold improvements 609 609 Construction in process 115 115 5,350 5,630 Less: accumulated depreciation (4,287) (4,283) $ 1,063 $ 1,347

Accrued Expenses and Other Cu_2

Accrued Expenses and Other Current Liabilities (Tables)	6 Months Ended
	Jun. 30, 2022
Payables and Accruals [Abstract]
Schedule of Accrued Expenses and Other Current Liabilities	Accrued expenses and other current liabilities consisted of: June 30, 2022 December 31, 2021 Accrued expenses: Selling, general and administrative expenses $ 7,016 $ 6,124 Research and development expenses 3,086 6,857 Payroll expenses 7,332 7,569 Product revenue allowances 23,126 26,521 Other 2,293 2,057 Total accrued expenses 42,853 49,128 Other current liabilities: Lease liability 2,356 2,094 Total other current liabilities 2,356 2,094 Total accrued expenses and other current liabilities $ 45,209 $ 51,222

Long-term Debt (Tables)

Long-term Debt (Tables)	6 Months Ended
	Jun. 30, 2022
Debt Disclosure [Abstract]
Schedule of Long-term Debt Instruments	The long-term debt balance is comprised of the following: June 30, 2022 December 31, 2021 Face amount $ 130,000 $ 130,000 Front end fees (559) (717) Debt issuance costs (3,258) (4,165) Back end fees 1,300 1,300 Long-term debt, net $ 127,483 $ 126,418

Stockholders' Equity (Tables)

Stockholders' Equity (Tables)	6 Months Ended
	Jun. 30, 2022
Equity [Abstract]
Schedule of Warrants Outstanding	As of June 30, 2022, the Company had the following warrants outstanding to purchase shares of Common Stock: Number of Shares Exercise Price Per Share Expiration Date 2,500,000 $1.60 November 18, 2024

Stock-based Compensation (Table

Stock-based Compensation (Tables)	6 Months Ended
	Jun. 30, 2022
Share-Based Payment Arrangement [Abstract]
Schedule of Allocated Stock-Based Compensation Expense	The Company recorded stock-based compensation expense related to stock options and shares issued under the Company's 2010 Stock Incentive Plan and 2017 Employee Stock Purchase Plan (2017 Plan) in the following expense categories of its accompanying consolidated statements of operations for the three and six months ended June 30, 2022 and 2021: Three Months Ended Six Months Ended 2022 2021 2022 2021 Cost of product sales $ 7 $ 6 $ 20 $ 17 Research and development 233 286 429 567 General and administrative 3,204 2,441 4,995 4,759 $ 3,444 $ 2,733 $ 5,444 $ 5,343
Schedule of Stock Option Activity	The following table summarizes the activity related to stock option grants to employees and non-employees for the six months ended June 30, 2022: Shares Weighted Weighted Outstanding at December 31, 2021 7,958,781 $ 8.87 6.50 Granted 2,902,370 1.88 Exercised (67,125) 1.63 Expired (135,983) 8.89 Forfeited (422,129) 3.86 Outstanding at June 30, 2022 10,235,914 $ 7.65 6.62 Exercisable at June 30, 2022 5,819,746 $ 10.37 5.26 Vested and expected to vest at June 30, 2022 9,342,884 $ 7.65 6.62
Schedule of Fair Value Options using Black-Scholes Pricing Model	The grant date fair value of each stock option grant, other than market-based stock option grants, was estimated at the time of grant using the Black-Scholes option-pricing model using the following weighted average assumptions: Six Months Ended June 30, 2022 2021 Risk free interest rate 1.82 % 1.00 % Expected term (in years) 6.08 6.08 Expected volatility 72.67 % 74.28 % Annual dividend yield 0.00 % 0.00 % Fair value of common stock $ 1.90 $ 3.52 each stock option grant, as well as the derived service period for these awards, was estimated at the time of grant using a Monte Carlo simulation based on the following assumptions: Six Months Ended 2022 Risk free rates of return 1.70 % Expected volatility 75.00 % Annual dividend yield — % The Company calculated the fair value of each option grant and the shares issued under the 2017 Plan on the respective dates of grant using the following weighted average assumptions: Six Months Ended June 30, 2022 2021 Risk free interest rate 0.22 % 0.09 % Expected term (in years) 0.5 0.5 Expected volatility 88.56 % 86.88 % Annual dividend yield 0.00 % 0.00 %
Schedule of Nonvested Restricted Stock Units Activity	The following table summarizes the activity related to RSUs granted to employees for the six months ended June 30, 2022: Shares Outstanding at December 31, 2021 1,959,358 Granted 1,105,246 Vested and settled (598,775) Expired/forfeited/canceled (264,146) Outstanding at June 30, 2022 2,201,683 Expected to vest at June 30, 2022 2,201,683

Liquidity (Details)

Liquidity (Details) - USD ($) $ in Thousands	3 Months Ended				6 Months Ended
	Jun. 30, 2022	Mar. 31, 2022	Jun. 30, 2021	Mar. 31, 2021	Jun. 30, 2022	Jun. 30, 2021	Dec. 31, 2021
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Cash and cash equivalents	$ 78,264				$ 78,264		$ 110,502
Net loss	19,397	$ 25,333	$ 23,502	$ 26,053	44,730	$ 49,555
Cash used in operating activities					(32,473)	$ (50,518)
Accumulated deficit	$ 654,791				$ 654,791		$ 610,061

Basis of Presentation and Sum_4

Basis of Presentation and Summary of Significant Accounting Policies - Concentration of Credit Risk (Details) - Customer Concentration Risk - Five Customers	3 Months Ended	6 Months Ended
	Jun. 30, 2022	Jun. 30, 2022
Accounts Receivable
Concentration Risk [Line Items]
Concentration risk (as a percent)		40%
Sales Revenue, Net
Concentration Risk [Line Items]
Concentration risk (as a percent)	26%	29%

Basis of Presentation and Sum_5

Basis of Presentation and Summary of Significant Accounting Policies - Restricted Cash (Details) - USD ($) $ in Thousands	Jun. 30, 2022	Dec. 31, 2021
Prepaid Expenses and Other Current Assets
New Accounting Pronouncements or Change in Accounting Principle [Line Items]
Restricted cash	$ 7	$ 13

Basis of Presentation and Sum_6

Basis of Presentation and Summary of Significant Accounting Policies - Antidilutive Shares Excluded From Computation of Net Loss Per Share (Details) - shares	6 Months Ended
	Jun. 30, 2022	Jun. 30, 2021
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Securities excluded from computation of net loss per common share (in shares)	15,145,735	10,989,547
Stock options
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Securities excluded from computation of net loss per common share (in shares)	10,235,914	7,980,424
Restricted stock units
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Securities excluded from computation of net loss per common share (in shares)	2,201,683	2,198,766
Common stock warrants
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Securities excluded from computation of net loss per common share (in shares)	2,500,000	810,357
Employee stock purchase plan
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Securities excluded from computation of net loss per common share (in shares)	208,138	0

Inventory (Details)

Inventory (Details) - USD ($) $ in Thousands	Jun. 30, 2022	Dec. 31, 2021
Inventory Disclosure [Abstract]
Raw materials	$ 2,508	$ 3,504
Work-in-process	5,989	4,816
Finished goods	2,476	3,527
Total inventory	$ 10,973	$ 11,847

Property and Equipment - Schedu

Property and Equipment - Schedule of Property and Equipment (Details) - USD ($) $ in Thousands	Jun. 30, 2022	Dec. 31, 2021
Property, Plant and Equipment [Line Items]
Property and equipment, gross	$ 5,350	$ 5,630
Less: accumulated depreciation	(4,287)	(4,283)
Property and equipment, net	1,063	1,347
Computer equipment and software
Property, Plant and Equipment [Line Items]
Property and equipment, gross	1,199	1,173
Furniture and fixtures
Property, Plant and Equipment [Line Items]
Property and equipment, gross	366	366
Machinery and equipment
Property, Plant and Equipment [Line Items]
Property and equipment, gross	3,061	3,367
Leasehold improvements
Property, Plant and Equipment [Line Items]
Property and equipment, gross	609	609
Construction in process
Property, Plant and Equipment [Line Items]
Property and equipment, gross	$ 115	$ 115

Property and Equipment - Narrat

Property and Equipment - Narrative (Details) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2022	Jun. 30, 2021	Jun. 30, 2022	Jun. 30, 2021
Property, Plant and Equipment [Line Items]
Depreciation	$ 137	$ 119	$ 255	$ 323
Inventory
Property, Plant and Equipment [Line Items]
Depreciation			651
Prepaid expenses and other assets
Property, Plant and Equipment [Line Items]
Depreciation			$ 10

Accrued Expenses and Other Cu_3

Accrued Expenses and Other Current Liabilities (Details) - USD ($) $ in Thousands	Jun. 30, 2022	Dec. 31, 2021
Accrued expenses:
Selling, general and administrative expenses	$ 7,016	$ 6,124
Research and development expenses	3,086	6,857
Payroll expenses	7,332	7,569
Product revenue allowances	23,126	26,521
Other	2,293	2,057
Total accrued expenses	42,853	49,128
Other current liabilities:
Lease liability	2,356	2,094
Total other current liabilities	2,356	2,094
Total accrued expenses and other current liabilities	$ 45,209	$ 51,222

Licensing Revenue (Details)

Licensing Revenue (Details) - USD ($) $ in Thousands		1 Months Ended	12 Months Ended
	Dec. 29, 2020	Jan. 31, 2021	Dec. 31, 2019
Currax License Agreement
Research and Development Arrangement, Contract to Perform for Others [Line Items]
Upfront payment received			$ 3,730
Additional revenue eligible and held in escrow	$ 750
Royalty Agreement Terms
Research and Development Arrangement, Contract to Perform for Others [Line Items]
Sales milestone payments eligible to be received (up to)		$ 1,000

Long-term Debt - Narrative (Det

Long-term Debt - Narrative (Details) - Senior Notes - USD ($) $ in Thousands		3 Months Ended				6 Months Ended
	Sep. 12, 2019	Jun. 30, 2022	Jun. 30, 2021	Sep. 30, 2020	Dec. 31, 2019	Jun. 30, 2022	Jun. 30, 2021	Dec. 01, 2020	Feb. 13, 2020
Debt Instrument [Line Items]
Bearing fixed interest, percentage rate	10.75%
Equal quarterly installments of principal repayment	5 years
Note Purchase Agreement
Debt Instrument [Line Items]
Debt maximum borrowing capacity	$ 130,000
Debt face amount	$ 80,000
Prepayment fee, after second and before third anniversary	2%
Prepayment fee, after third and before fourth anniversary	1%
Prepayment premium amount	$ 0
Debt covenant, cash and cash equivalents	$ 30,000
Interest expense		$ 4,086	$ 4,012			$ 8,159	$ 7,888
Note Purchase Agreement | Debt Instrument, Redemption, Period One
Debt Instrument [Line Items]
Debt instrument, make-whole provision, payment accrual period	30 months
Note Purchase Agreement | Debt Instrument, Redemption, Period Two
Debt Instrument [Line Items]
Debt instrument, make-whole provision, payment accrual period	15 months
Note Purchase Agreement - First Delayed Draw Notes
Debt Instrument [Line Items]
Debt face amount									$ 30,000
Note Purchase Agreement - First Delayed Draw Notes | Quarter Ended December 31, 2019
Debt Instrument [Line Items]
Debt issuance criteria term, net sales and royalties benchmark					$ 9,000
Note Purchase Agreement - Third Delayed Draw Notes
Debt Instrument [Line Items]
Debt face amount								$ 20,000
Note Purchase Agreement - Third Delayed Draw Notes | Quarter Ended September 30, 2020
Debt Instrument [Line Items]
Debt issuance criteria term, net sales and royalties benchmark				$ 14,500

Long-term Debt - Schedule of Lo

Long-term Debt - Schedule of Long-term Debt (Details) - USD ($) $ in Thousands	Jun. 30, 2022	Dec. 31, 2021
Short-term Debt [Line Items]
Long-term debt, net	$ 127,483	$ 126,418
Note Purchase Agreement | Senior Notes
Short-term Debt [Line Items]
Face amount	130,000	130,000
Front end fees	(559)	(717)
Debt issuance costs	(3,258)	(4,165)
Back end fees	1,300	1,300
Long-term debt, net	$ 127,483	$ 126,418

Employee Benefit Plans (Details

Employee Benefit Plans (Details) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2022	Jun. 30, 2021	Jun. 30, 2022	Jun. 30, 2021
Defined Contribution Plan Disclosure [Line Items]
Accrued liabilities related to the Company match	$ 91		$ 91
Norway and UK employee plans
Defined Contribution Plan Disclosure [Line Items]
Defined contribution plan, cost	$ 2	$ 1	$ 3	$ 3

Stockholders' Equity - Narrativ

Stockholders' Equity - Narrative (Details) - USD ($)	Jun. 30, 2022	Nov. 18, 2021
Warrants Expiring November 15, 2024
Class of Stock [Line Items]
Number of shares called by warrants (in shares)		2,500,000
Warrants exercise price (in USD per share)	$ 1.60	$ 1.60
Warrants and rights outstanding		$ 2,009,000
Warrants Expiring September 12, 2022
Class of Stock [Line Items]
Warrants exercise price (in USD per share)		$ 6.72
Warrants cancelled (in shares)		810,357

Stockholders' Equity - Schedule

Stockholders' Equity - Schedule of Warrants Outstanding (Details) - Warrants Expiring November 15, 2024 - $ / shares	Jun. 30, 2022	Nov. 18, 2021
Class of Stock [Line Items]
Warrants outstanding (in shares)	2,500,000
Warrants outstanding, measurement input (in USD per share)	$ 1.60	$ 1.60

Stock-based Compensation - Allo

Stock-based Compensation - Allocated Stock-Based Compensation Expense (Details) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2022	Jun. 30, 2021	Jun. 30, 2022	Jun. 30, 2021
Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]
Stock-based compensation expense	$ 3,444	$ 2,733	$ 5,444	$ 5,343
Cost of product sales
Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]
Stock-based compensation expense	7	6	20	17
Research and development
Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]
Stock-based compensation expense	233	286	429	567
General and administrative
Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]
Stock-based compensation expense	$ 3,204	$ 2,441	$ 4,995	$ 4,759

Stock-based Compensation - Narr

Stock-based Compensation - Narrative (Details) - USD ($) $ / shares in Units, $ in Thousands		3 Months Ended		6 Months Ended
	Jun. 15, 2022	Jun. 30, 2022	Jun. 30, 2021	Jun. 30, 2022	Jun. 30, 2021
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock-based compensation expense		$ 3,444	$ 2,733	$ 5,444	$ 5,343
Plan options contractual life (up to)				10 years
Award vesting period				4 years
Service Based Stock Options
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Award vesting period				4 years	4 years
Stock options to purchase shares (in shares)				2,902,370	1,542,696
Weighted average grant date fair value (usd per share)				$ 1.19	$ 2.29
Unrecognized cost related to unvested RSUs expected to vest		6,655		$ 6,655
Estimated weighted-average amortization period				2 years 3 months 10 days
Market Based Stock Options
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Award vesting period				2 years
Stock options to purchase shares (in shares)				959,215
Restricted stock units
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock-based compensation expense	$ 1,346
Award vesting period				4 years
Granted (in shares)				1,105,246
Restricted shares fair value at grant date (usd per share)				$ 1.85
Vested and settled (in shares)	248,830			598,775
Restricted Stock Units, Service-Based
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Unrecognized cost related to unvested RSUs expected to vest		5,041		$ 5,041
Estimated weighted-average amortization period				2 years 7 months 17 days
Restricted Stock Units, Performance-Based
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Unrecognized cost related to unvested RSUs expected to vest		1,749		$ 1,749
NASDAQ Inducement Grant Exception | Restricted stock units
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Granted (in shares)				60,000
2017 Plan
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock-based compensation expense		$ 74	$ 91	$ 162	$ 199
2017 Plan | Employee Stock
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
ESPP purchase price of common stock, percent of market price				85%
Inventory
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock-based compensation expense				$ 85
Prepaid expenses and other assets
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock-based compensation expense				$ 1

Stock-based Compensation - Stoc

Stock-based Compensation - Stock Option Activity (Details) - Service Based Stock Options - $ / shares	6 Months Ended		12 Months Ended
	Jun. 30, 2022	Jun. 30, 2021	Dec. 31, 2021
Shares
Beginning balance (in shares)	7,958,781
Granted (in shares)	2,902,370	1,542,696
Exercised (in shares)	(67,125)
Expired (in shares)	(135,983)
Forfeited (in shares)	(422,129)
Ending balance (in shares)	10,235,914		7,958,781
Exercisable (in shares)	5,819,746
Vested and expected to vest (in shares)	9,342,884
Weighted average exercise price per share
Beginning balance (usd per share)	$ 8.87
Granted (usd per share)	1.88
Exercised (usd per share)	1.63
Expired (usd per share)	8.89
Forfeited (usd per share)	3.86
Ending balance (usd per share)	7.65		$ 8.87
Exercisable (usd per share)	10.37
Vested and expected to vest (usd per share)	$ 7.65
Weighted average remaining contractual life
Options outstanding, weighted average remaining contractual life	6 years 7 months 13 days		6 years 6 months
Options exercisable, weighted average remaining contractual life	5 years 3 months 3 days
Vested and expected to vest, weighted average remaining contractual life	6 years 7 months 13 days

Stock-based Compensation - Fair

Stock-based Compensation - Fair Value Options using Black-Scholes Pricing Model (Details) - $ / shares	6 Months Ended
	Jun. 30, 2022	Jun. 30, 2021
2017 Plan
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Risk free interest rate	0.22%	0.09%
Expected term (in years)	6 months	6 months
Expected volatility	88.56%	86.88%
Annual dividend yield	0%	0%
Stock options
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Risk free interest rate	1.82%	1%
Expected term (in years)	6 years 29 days	6 years 29 days
Expected volatility	72.67%	74.28%
Annual dividend yield	0%	0%
Fair value of common stock (usd per share)	$ 1.90	$ 3.52
Market Based Stock Options
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Risk free rates of return	1.70%
Expected volatility	75%
Annual dividend yield	0%

Stock-based Compensation - Rest

Stock-based Compensation - Restricted Stock Units Activity (Details) - Restricted stock units - shares		6 Months Ended
	Jun. 15, 2022	Jun. 30, 2022
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward]
Beginning balance (in shares)		1,959,358
Granted (in shares)		1,105,246
Vested and settled (in shares)	(248,830)	(598,775)
Expired/ forfeited/ canceled (in shares)		(264,146)
Ending balance (in shares)		2,201,683
Expected to vest at end of period (in shares)		2,201,683

Subsequent Events (Details)

Subsequent Events (Details) - Subsequent Event - USD ($) $ in Thousands	Aug. 10, 2022	Aug. 09, 2022
Subsequent Event [Line Items]
Trailing twelve month net revenue covenant	$ 85,000	$ 90,000
Fee due on the maturity date of the note purchase agreement	$ 780